Prediction: This Will Be the Biggest Pharma Stock in 10 Years
24/7 Wall St. Insights Eli Lilly and Co. (NYSE: LLY) is the clear frontrunner to be the largest pharmaceutical stock in 2034.
1 Unstoppable Stock That Could Join the $1 Trillion Club in 2025
Most of the stocks in the trillion-dollar club are tech stocks. One of the biggest names in healthcare, Eli Lilly, could join those ranks within the next few months.
Prediction: This Will be Eli Lilly's Next Big Move.
Eli Lilly's stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring sales thanks to its dominance in the high-growth weight loss drug market.
Lilly Gets FDA Approval for Eczema Drug Ebglyss
The FDA approves Lilly's Ebglyss based on data from ADvocate 1, ADvocate 2 and ADhere studies.
FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis
EBGLYSS provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topicals Patients treated with EBGLYSS experienced significant skin cl...
6 Incredible Reasons to Invest in Eli Lilly
The pharma giant's financial results have been strong, largely thanks to its new crown jewel. But there may be more to come as the company's development pipeline looks incredibly exciting.
Eli Lilly Invests $1.8B To Expand Drug Output in Ireland
Eli Lilly (LLY) said Thursday it will spend $1.8 billion to expand production in Ireland of its popular diabetes and weight-loss drugs, as well as some active ingredients used in its Alzheimer's tr...
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks
Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.
2 Weight Loss Drug Stocks Worth Stashing Away for Years
As the high-growth trade fizzles out in September, even some top-tier secular growth plays will take an outsized hit to the chin.
Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes
In QWINT-2, efsitora helped adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists achieve an A1C below 7% Detailed results were published in The New England Journal...
This Unstoppable Stock Has Gained 100,203% Over The Last 50 Years, Creating Many Millionaires in the Process. Here Are 3 Reasons I Think It Will Co...
Glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro and Zepbound have been multibillion-dollar hits for Lilly, and their growth could just be getting started. Lilly is about to enter the Alzh...
Beyond Mounjaro and Zepbound: 6 Other Drugs That Could Be Blockbusters for Eli Lilly
Eli Lilly has three likely blockbuster drugs that are relatively new to the market. Its pipeline features three other late-stage candidates with blockbuster potential.
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
Merck & Co., Inc. NYSE: MRK is one of the largest pharmaceutical firms in the world. The firm ranks fourth behind giants like Eli Lilly NYSE: LLY and Novo Nordisk NYSE: NVO, with a market capitaliz...
The Big 3: LLY, XOM & PLTR
Joe Tigay joins Ben Lichtenstein and Nicole Petallides to break down the technical trends in Eli Lilly (LLY), Exxon Mobil (XOM), and Palantir (PLTR). ======== Schwab Network ======== Empowering eve...
Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study Goals
Data from two late-stage studies show that LLY's once-weekly insulin injections achieved results that are similar to daily insulin shots.
Related Companies